The clinical trials process used to test new drugs for the sick is broken and needs to be retooled.
Trials are the pivotal stage in the development of life-improving drugs before they go on the market. But they have grown too costly and lengthy, and are freighted with inefficiencies.
The industry that’s evolved to conduct and manage clinical trials has lost touch with its customers – the makers of new drugs – and to a degree with their acquiescence. The increasingly-challenged model of a cartel of service providers delivering trials in a formulaic, one-size-fits-all fashion is proving ultimately detrimental to the interests of consumers as well.
There’s a need for fresh approaches to designing, conducting and managing trials. And there’s a lot of room for improvement:
Today, clinical trials are plagued by a lack of communication, mutual trust and transparency among the various stakeholders. Investigators, service providers and sponsors pursue interests that can be at odds
Some sponsors have begun to question the old ways of approaching clinical trials. Those who scrutinize their service providers better and take more ownership of the process are advancing their ultimate goal of getting reliable answers as quickly as possible to a prospective drug's viability.